3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
2
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
2
Drug-Related Side Effects and Adverse Reactions
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Social Determinants of Health
×
Clear all
NCT05096338
2026-03-23
PCT
Abramson Cancer Center at Penn Medicine
Active not recruiting
200 enrolled
NCT05078190
2025-11-06
CCT2
Abramson Cancer Center at Penn Medicine
Active not recruiting
200 enrolled